Advion develops, manufactures and globally supports mass spectrometers, novel sample introduction and assay solutions, chip- based ion sources, chromatography systems, microfluidic flow chemistry systems and consumables for life science and related industries. We seek to enhance analysis performance and workflows. Using our deep scientific and engineering knowledge of mass spectrometry and microfludics, we leverage our passionate employees’ commitment to create quality, flexible and fit-for- purpose solutions.

Herborium Group is a developer and marketer of herbal nutritional supplements. Herborium's product line includes Traditional Chinese Medicine herbal blends designed to clear up acne (AcnEase), boost energy (Energy Restoration), and heighten sexual performance (Lasting Pleasure for women, MaleForce for men). Herborium sells it products in the US, the UK, and continental Europe through a network of distributors, specialty retailers, such as natural foods stores, and online marketplaces. The company's founder, president and CEO Agnes Olszewski and director James Gilligan hold about 70% of the company's shares.

Quality Assured Services (QAS) is a direct marketer of point-of-care and self-testing diagnostic products. It distributes easy-to-use diagnostic kits directly to consumers' homes, as well as to health professionals and home health care providers. Its products include anticoagulation tests, cholesterol tests, and other products that monitor and diagnose such conditions as blood pressure, diabetes, lung function, and infectious diseases. The company also provides telemedicine support, patient management software, insurance verification, and billing services. QAS is a subsidiary of diagnostic products firm Inverness Medical Innovations.

Xceed Molecular is working to exceed the expectations of researchers performing gene expression tests. The company's flow-thru chip technology allows biotechnology and pharmaceutical companies to conduct genetic screening research. Its Ziplex system is used for automated gene expression analysis. Other products include assay reagent kits, sample preparation reagents, and its TipChip disposable microarrays. The company also produces chips to detect specific diseases and is working to speed up the time needed to process samples. Xceed Molecular, which was established in 2001, has facilities in Canada and the US.

OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

Peregrine Pharmaceuticals, Inc. company was founded in 1981 and is based in Tustin, California. Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and manufacture of monoclonal antibodies for the treatment of cancer and viral infections. The company develops clinical programs with its novel compounds bavituximab and Cotara, which are the clinical candidates under its anti-phosphatidylserine therapeutics and tumor necrosis therapy platforms. Its pipeline products comprise Bavituximab Plus Docetaxel, and Bavituximab plus carboplatin and paclitaxel, which are Phase II clinical trial products for treating advanced breast cancer patients; and Bavituximab plus carboplatin and paclitaxel, a Phase II clinical trial product for the treatment of non-small cell lung cancer, as well as Bavituximab, which is in Phase I monotherapy repeat dose safety study for treating solid tumor cancers, and in Phase Ib repeat dose safety study for the treatment of chronic hepatitis C virus infection co-infected with HIV. In addition, its pipeline products include Cotara, a product in Phase II, as well as a dosimetry and dose confirmation study for the treatment of glioblastoma multiforme, an aggressive form of brain cancer. Further, Peregrine, through its wholly owned subsidiary, Avid Bioservices, Inc., provides contract manufacturing services for biotechnology and biopharmaceutical companies, from pre-clinical drug supplies up through commercial-scale drug manufacture. Further, it provides services in support of Peregrine's product pipeline, including manufacture and scale-up of pre-clinical and clinical drug supplies.

Formatech provides contract development services for pharmaceutical companies, including cell culture and fermentation, pre-formulation, dosage form, and purification development services. Its dosage forms include liquid, controlled release, tablets, capsules as well as topicals, such as gels, ointments, and creams. It also provides project management services to its contract development customers. The company also offers manufacturing services, such as aseptic fill, finishing, and lyophilization. Formatech's specializations include small molecules, vaccines, and monoclonal antibodies.

Laboratorios Farmacéuticos ROVI manufactures and sells pharmaceuticals in Spain and the rest of Europe. Its best selling prescription drugs include Hibor, (a brand name heparin used to prevent blood clots during surgery), osteoporosis drug Osseor, and angina drug Corlentor. ROVI's handful of OTC products include Autan insect repellant and the Enerzona line of dietary wellness products.In 2009 the company licensed Novavax's VLP vaccine technology which it will use to create a flu vaccine for the Spanish government. The E60 million ($84 million) program is being sponsored by the Spanish Ministry of Health. ROVI was founded in 1946 and went public on the Spanish Stock Exchange in late 2007.

Helicon Therapeutics is a development-stage biotechnology firm working on new therapies for memory loss and other cognition disorders. The company's research and development efforts focus on a protein that controls the signal pathway key to forming long-term memories. Scientists working for Helicon Therapeutics discovered the protein while studying the fruit fly genome. The company is working on drugs to not only maintain memory but also possibly to prevent memories from forming in the first place. Lead drug candidate HT-0712 has shown the ability to improve long-term memory in rats. Other candidates are in early stages of development.

Vernalis plc company was founded in 1986 and is based in Winnersh, the United Kingdom. Vernalis plc, a development stage pharmaceutical company, engages in de novo structure and fragment-based drug discovery, and pre-clinical and clinical development primarily in Europe and North America. It primarily involves in the research, development, and commercialization of pharmaceutical products for a range of medical disorders. The company’s products include Frovatriptan, a 5-HT1B/1D receptor agonist, which is approved as an acute oral treatment for migraine headache and its associated symptoms; and Apokyn, an acute intermittent therapy for the treatment of re-emergence of Parkinson’s disease symptoms associated with advanced Parkinson’s disease. Its product pipeline comprises V3381/Indantadol, a Phase IIb study novel small molecule with a dual mechanism for the treatment of neuropathic pain; V85546, a Phase I study selective MMP 12 inhibitor for inflammation; V1512/Levodopa methyl ester/carbidopa, a Phase II trial product for Parkinson’s disease treatment; V2006, an adenosine A2A receptor antagonist in Phase IIa study for the treatment of Parkinson’s disease; NVP-AUY922, a novel Hsp90 inhibitor, which is in Phase I program for the treatment of a range of cancers, including solid tumors and hematological cancers; V158866 Fatty Acid Amide Hydrolase, a pre-clinical stage product for pain management; V10153, a Phase IIa recombinant human thrombolytic protein for the treatment of acute ischemic stroke; and V24343, a Phase I study cannabinoid type 1 receptor antagonist for the treatment of obesity, diabetes, and related disorders.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.